A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma

Pemigatinib, a pan-FGFR inhibitor, is approved to treat intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusion mutations. Improving its targeting of FGFR2 fusions remains an unmet clinical need due to its pan selectivity and resistance. Here, we report a cholesterol-conjugated DNA/RNA heterodu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Zhenzhen, Zhang, Baohuan, Zhou, Xuxuan, Yuan, Hui, Gao, Chongqing, Liu, Lihao, Xiao, Yang, Zhang, Jichun, Hong, Jian, Liang, Junjie, Chen, Dong, Yao, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589379/
https://www.ncbi.nlm.nih.gov/pubmed/37869260
http://dx.doi.org/10.1016/j.omtn.2023.102047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589379/
https://www.ncbi.nlm.nih.gov/pubmed/37869260
http://dx.doi.org/10.1016/j.omtn.2023.102047

Ejemplares similares